– USA, MA – BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced that at BIND’s annual meeting of stockholders held today the company’s stockholders elected Mr. Charles A. Rowland, Jr., CPA, most recently the Vice President and Chief Financial Officer of ViroPharma Incorporated, to its Board of Directors.
“As the former CFO of a leading biotechnology company, Charlie brings valuable experience and skills to help BIND advance as the company approaches an important inflection point in achieving clinical milestones and increases the scope and pace of our drug development programs,” said Scott Minick, Chief Executive Officer at BIND. “Charlie has demonstrated leadership in building value in high growth businesses by strategically investing in the future while balancing prudent financial management and we look forward to his contributions and guidance at BIND.”
Mr. Rowland has more than 30 years of experience in financial management and strategic business operations. He served as the Vice President and Chief Financial Officer of ViroPharma Incorporated, an international biopharmaceutical company, until it was acquired by Shire plc in January 2014. He also served as senior vice president of finance, with responsibilities for leading the treasury, tax, investor relations and business planning groups. Prior to joining ViroPharma in 2008, Mr. Rowland was the Executive Vice President and Chief Financial Officer, as well as the interim Co-Chief Executive Officer, for Endo Pharmaceuticals Inc., a specialty pharmaceutical company with a primary focus in pain management, where he served from 2006 to 2008. At Endo, Mr. Rowlanddrove the strategic planning process, including the design and implementation of the company’s mid and long-term strategy. From 2004 to 2006, Mr. Rowland was the Senior Vice President and Chief Financial Officer of Biovail Corporation, an international pharmaceutical company, where he directed all financial activities for the company including tax, treasury, accounting, financial analysis, investor relations as well as all aspects of information technology. Mr. Rowland previously held positions of increasing responsibility at Breakaway Technologies, Inc.,Pharmacia Corporation, Novartis AG and Bristol-Myers Squibb Co.
“BIND’s Accurin platform represents a major advance in the biopharmaceutical industry and the company’s pipeline of product candidates, both internal and partnered, have the potential to provide important clinical benefits to patients,” said Mr. Rowland. “I am looking forward to working with management and the BIND board as the company enters the next stage of its evolution.”
About BIND Therapeutics
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its Medicinal Nanoengineering® platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND’s lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. BIND has announced collaborations with Amgen Inc., Pfizer Inc. and AstraZeneca AB to develop Accurins based on therapeutic payloads from their product pipelines. BIND’s platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brighamand Women’s Hospital/Harvard Medical School of BIND’s scientific founders and directors Dr. Robert Langer and Dr. Omid Farokhzad.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.